Seres Therapeutics Inc (NASDAQ: MCRB) kicked off on Tuesday, down -6.90% from the previous trading day, before settling in for the closing price of $0.82. Over the past 52 weeks, MCRB has traded in a range of $0.54-$1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 477.44%. While this was happening, its average annual earnings per share was recorded 86.52%. With a float of $124.81 million, this company’s outstanding shares have now reached $170.20 million.
The extent of productivity of a business whose workforce counts for 233 workers is very important to gauge. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -258259.37%.
Seres Therapeutics Inc (MCRB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Seres Therapeutics Inc is 26.90%, while institutional ownership is 23.58%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.52% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Take a look at Seres Therapeutics Inc’s (MCRB) current performance indicators. Last quarter, stock had a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2180.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
The latest stats from [Seres Therapeutics Inc, MCRB] show that its last 5-days average volume of 1.29 million was inferior to 1.33 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 17.17%. Additionally, its Average True Range was 0.07.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 28.96%, which indicates a significant increase from 6.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.37% in the past 14 days, which was lower than the 92.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8227, while its 200-day Moving Average is $0.8852. Now, the first resistance to watch is $0.8119. This is followed by the second major resistance level at $0.8576. The third major resistance level sits at $0.8885. If the price goes on to break the first support level at $0.7353, it is likely to go to the next support level at $0.7044. The third support level lies at $0.6587 if the price breaches the second support level.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
The company with the Market Capitalisation of 130.84 million has total of 170,738K Shares Outstanding. Its annual sales at the moment are 126,330 K in contrast with the sum of -113,720 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was 88,780 K.
